" class="no-js "lang="en-US"> Virion Therapeutics Presents Promising Preclinical Cancer Data
Wednesday, June 19, 2024

Virion Therapeutics Presents Promising Preclinical Cancer Data When Using a Novel Genetically Encoded Checkpoint Modifier-Based Immunotherapy

Virion Therapeutics, a clinical-stage biotech company focused on the development of novel, adaptable, and accessible CD8+ T cell-based technologies focused on cancers and infectious diseases, presented data today of a genetically encoded checkpoint modifier-based immunotherapy, which enhances CD8+ T cell activation, in a fast-growing preclinical tumor model at the ESMO Target Anti cancer Therapies Congress in Paris France.

Top line results, following a single intramuscular injection of this novel immunotherapy include:

  • Enhanced immune responses (10- to 15-fold) to oncogenic antigens
  • At study completion, 100% survival (n=30/30), 100% initial tumor clearance (n=30/30), and 93% of animals were tumor free (n=28/30)
    • In contrast, all mice treated with a control vaccine experienced rapid tumor growth and death by Day 30 (n=20)
  • These results were durable and reproducible across multiple treatment groups and studies

 

“Glycoprotein D (gD), when genetically expressed as a fusion protein with antigen(s) of choice, enhances, broadens, and prolongs CD8+ T cell responses.  In this preclinical model of fast-growing HPV-16-associated tumors, a gD-based immunotherapy against HPV-16 provided incredibly strong protection against tumor growth and death,” said Hildegund Ertl, MD, Professor, Vaccine & Immunotherapy Center, at The Wistar Institute in Philadelphia PA and Scientific Co-Founder of Virion Therapeutics. “Targeting different checkpoints of early T cell activation represents a novel approach to overcoming T cell impairments during tumor progression and these data further support its potential application, alone or in combination with other checkpoint inhibitors, for a wide range of cancers.”

“These preclinical oncology data demonstrated treatment responses which were profound, durable, and reproducible – and show clear differentiation to any other immunotherapy or vaccine in development. We are excited to be advancing our checkpoint modifier pipeline, not only with IND-enabling activities for our oncology program, but also, VRON-0200, for chronic HBV, which is heading to the clinic this summer,” said Andrew Luber, Pharm.D., President, and chief executive officer of Virion.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more